Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib

IMPORTANCE: Gastrointestinal stromal tumors (GISTs) are life-threatening when metastatic or not amenable to surgical removal. In a few patients with advanced GISTs refractory to imatinib mesylate, treatment with sunitinib malate followed by regorafenib provides tumor control; however, additional act...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Oncol
Asıl Yazarlar: Schuetze, Scott M., Bolejack, Vanessa, Thomas, Dafydd G., von Mehren, Margaret, Patel, Shreyaskumar, Samuels, Brian, Choy, Edwin, D’Amato, Gina, Staddon, Arthur P., Ganjoo, Kristen N., Chow, Warren A., Rushing, Daniel A., Forscher, Charles A., Priebat, Dennis A., Loeb, David M., Chugh, Rashmi, Okuno, Scott, Reinke, Denise K., Baker, Laurence H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2018
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6145709/
https://ncbi.nlm.nih.gov/pubmed/29710216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.0601
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller